Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Refractory or Relapsed Osteosarcoma
NCT01216826Phase 2Unknown
- Start
- Mar 2011
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in osteosarcoma (OS). Primary endpoint: Aim Response (Complete Response, Partial Response, or Stable Disease) up to 2 years. Status: unknown.
02
Drugs
everolimus
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT01216826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01216826.